Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CTX-1||CTX1||MDM4 inhibitor 8||CTX-1 binds to and inhibits Mdm4 (MdmX), which disrupts the interaction between Tp53 and Mdm4, leading to stabilization of Tp53 and potentially leading to increased tumor cell death (PMID: 26883273).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 loss||Advanced Solid Tumor||decreased response||CTX-1||Preclinical||Actionable||In a preclinical study, CTX-1 induced cell death in TP53-deficient human tumor cell lines in culture, but had a greater effect on cell lines with wild-type TP53 compared to isogenic cell lines with TP53 loss (PMID: 26883273).||26883273|
|TP53 wild-type||Advanced Solid Tumor||sensitive||CTX-1||Preclinical||Actionable||In a preclinical study, CTX-1 induced cell death in several solid tumor cell lines with wild-type TP53 in culture (PMID: 26883273).||26883273|
|TP53 mutant||Advanced Solid Tumor||sensitive||CTX-1||Preclinical||Actionable||In a preclinical study, CTX-1 induced increased Tp53 protein levels and cell death in human tumor cell lines with mutant Tp53 in culture (PMID: 26883273).||26883273|
|TP53 wild-type||acute myeloid leukemia||sensitive||CTX-1||Preclinical||Actionable||In a preclinical study, CTX-1 improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).||26883273|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|